Skip to content

NeoGenomics

US · NEO #2660 by market cap Listed 1970
14.82 -0.27 -1.79%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.59 Expensive vs history 90th percentile
5-year average 1.85 · #15 of 41 in Diagnostics & Research
P/E ratio -66.75 Cheap vs history 5th percentile
5-year average -21.50 · forward -59.03
P/S ratio 2.63 In line with history 40th percentile
5-year average 2.99 · forward 2.39 · #17 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
NeoGenomics (NEO) 1.92B -61.75 2.39 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value17.40 Economic moatNone UncertaintyHigh

Trading 17.4% below Morningstar's fair value estimate.

Fair value

NeoGenomics Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 8% discount to our quantitative fair value estimate of $17.40 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's solid growth increases our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its cash flow per share growth, which sits in the top 20% globally. This indicates a rapid rate of growth in cash flow available for reinvestment or return to shareholders, which contributes to our view that shares are undervalued.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.1%, a core component of profitability, lies in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

NeoGenomics discussion 0 comments

Add a comment